Pastorekova S, Zavadova Z, Kostal M, et al. A novel quasiviral agent, MaTu, is a two-component system[J]. Virology, 1992, 187(2): 620-626.
[2]
Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonicanhydrase and a putative helix-loop-helix DNA-binding segment[J]. Oncogene, 1994, 9(10): 2 877-2 888.
[3]
KizakaKondoh S, Tanaka S, Harada H, et al. The HIF-1-active microenvironment: an environmental target for cancer therapy[J]. Advanced Drug Delivery Reviews, 2009, 61(7-8): 623-632.
[4]
Huang LE, Bindra RS, Glazer PM, et al. Hypoxia-induced genetic instability: a calculated mechanism underlying tumor progression [J]. Journal of Molecular Medicine-Jmm, 2007, 85(2): 139-148.
[5]
Woelber L, Kress K, Kersten JF, et al. Carbonic anhydrase Ⅸ in tumor tissue and sera of patients with primary cervical cancer[J]. Bmc Cancer, 2011, 11: 10.
[6]
Eriksen JG, Overgaard J. Lack of prognostic and predictive value of CA Ⅸ in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study[C]//10th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology. Wolfsberg: AUSTRIA, 2007: 383-388.
[7]
Sherwood BT, Coquhoun AJ, Richardson D, et al. Carbonic anhydrase Ⅸ expression and outcome after radiotherapy for muscle-invasive bladder cancer [J]. Clinical Oncology, 2007, 19(10): 777-783.
[8]
Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAⅨ expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma[J]. International Journal of Cancer, 2008, 123(2): 395-400.
[9]
Kim SJ, Shin HJ, Jung KY, et al. Prognostic value of carbonic anhydrase Ⅸ and Ki-67 expression in squamous cell carcinoma of the tongue[J]. Japanese Journal of Clinical Oncology, 2007, 37(11): 812-819.
[10]
Ilie M, Mazure NM, Hofman V, et al. High levels of carbonic anhydrase Ⅸ in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer [J]. British Journal of Cancer, 2010, 102(11): 1 627-1 635.
Supuran CT. Development of small molecule carbonic anhydrase Ⅸ inhibitors. International Carbonic Anhydrase Ⅸ (CAⅨ) Symposium[M]. Brussels: BELGIUM, 2007: 39-40.
[13]
Casey JR, Morgan PE, Vullo D, et al. Carbonic anhydrase inhibitors: design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme Ⅸ [J]. Journal of Medicinal Chemistry, 2004, 47(9): 2 337-2 347.
[14]
Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors: design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase Ⅸ that inhibit isozyme Ⅸ-mediated acidification of hypoxic tumors [J]. Journal of Medicinal Chemistry, 2005, 48(15): 4 834-4 841.
[15]
Colinas PA, Bravo RD, Vullo D, et al. Carbonic anhydrase inhibitors: inhibition of cytosolic isoforms Ⅰ and Ⅱ, and extracellular isoforms Ⅳ, Ⅸ, and Ⅻ with sulfamides incorporating sugar moietie[J]. Bioorganic & Medicinal Chemistry Letters, 2007, 17(18): 5 086-5 090.
[16]
Thiry A, Supuran CT, Masereel B, et al. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs[J]. Journal of Medicinal Chemistry, 2008, 51(11): 3 051-3 056.
[17]
Lopez M, Paul B, Hofmann A, et al. S-glycosyl primary sulfonamidesn-a new structural class for selective inhibition of cancer-associated carbonic anhydrases[J]. Journal of Medicinal Chemistry, 2009, 52(20): 6 421-6 432.
[18]
Akurathi V, Dubois L, Lieuwes NG, et al. Synthesis and biological evaluation of a Tc-99m-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase Ⅸ expression in tumor hypoxia[J]. Nuclear Medicine and Biology, 2010, 37(5): 557-564.
[19]
Vullo D, Scozzafava A, Pastorekova S, et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme Ⅸ with fluorine-containing sulfonamides. The first subnanomolar CA Ⅸ inhibitor discovered[J]. Bioorganic & Medicinal Chemistry Letters, 2004, 14(9): 2 351-2 356
[20]
Zhang L, Cecic I, Cheng Z, et al. In Vitro evaluation of 18F-2,3,5,6-tetrafluoro-3’-sulfamoylbenzanilide as a potential PET probe for carbonic anhydrase Ⅸ[J]. Mol Imaging Biol, 2006, 8: 110.
[21]
Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics[J]. Nature Reviews Drug Discovery, 2006, 5(2): 147-159.
[22]
Chrastina A, Zavada J, Parkkila S, et al. Biodistribution and pharmacokinetics of I-125-labeled monoclonal antibody M75 specific for carbonic anhydrase Ⅸ, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma[J]. International Journal of Cancer, 2003, 105(6): 873-881.
[23]
Steffens MG, Boerman OC, Oosterwijk Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250[J]. Journal of Clinical Oncology, 1997, 15(4): 1 529-1 537.
[24]
Steffens MG, Boerman OC, de Mulder PHM, et al. Phase Ⅰ radioimmunotherapy of metastatic renal cell carcinoma with I-131-labeled chimeric monoclonal antibody G250 [J]. Clinical Cancer Research, 1999, 5(10): 3 268S-3 274S.
[25]
Brouwers AH, van Eerd JEM, Frielink C, et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with I-131, Y-90, Lu-177, or Re-186[J]. Journal of Nuclear Medicine, 2004, 45(2): 327-337.
[26]
Stillebroer AB, Oosterwijk E, Mulders PFA, et al. Radioimmunotherapy with lutetium-177 labeled monoclonal antibody cG250 in patients with advanced renal cell carcinoma[J]. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23(4): 523-524.
[27]
Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (I-124-cG250) and PET in patients with renal masses: a phase Ⅰ trial [J]. Lancet Oncology, 2007, 8(4): 304-310.
[28]
Troost EGC, Bussink J, Kaanders J, et al. Comparison of different methods of CA Ⅸ quantification in relation to hypoxia in three human head and neck tumor lines[J]. Radiotherapy and Oncology, 2005, 76(2): 194-199.
[29]
Hoeben BAW, Kaanders J, Franssen GM, et al. PET of hypoxia with Zr-89-labeled cG250-F(ab’)(2) in head and neck tumors[J]. Journal of Nuclear Medicine, 2010, 51(7): 1 076-1 083.
[30]
Carlin S, Khan N, Ku T, et al. Molecular targeting of carbonic anhydrase Ⅸ in mice with hypoxic HT29 colorectal tumor xenografts[J]. Plos One, 2010, 5(5): e10 857.
Juhasz M, Chen J, Lendeckel U, et al. Expression of carbonic anhydrase Ⅸ in human pancreatic cancer[J]. Alimentary Pharmacology & Therapeutics, 2003, 18(8): 837-846.
[34]
Hynninen P, Vaskivuo L, Saarnio J, et al. Expression of transmembrane carbonic anhydrases Ⅸ and Ⅻ in ovarian tumours[J]. Histopathology, 2006, 49(6): 594-602.
[35]
Svastova E, Hulikova A, Rafajova M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase Ⅸ to acidify extracellular pH [J]. Febs Letters, 2004, 577(3): 439-445.
[36]
Swietach P, Wigfield S, Supuran CT, et al. Cancer-associated, hypoxia-inducible carbonic anhydrase Ⅸ facilitates CO2 diffusion:International carbonic anhydrase Ⅸ (CA Ⅸ) Symposium[M]. Brussels: BELGIUM, 2007: 22-24.
[37]
Chiche J, Ilc K, Laferriere J, et al. Hypoxia-inducible carbonic anhydrase Ⅸ and Ⅻ promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH[J]. Cancer Research, 2009, 69(1): 358-368.
[38]
Svastova E, Zilka N, Zat’ovicova M, et al. Carbonic anhydrase Ⅸ reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin [J]. Experimental Cell Research, 2003, 290(2): 332-345.
[39]
Thiry A, Dogne JM, Masereel B, et al. Targeting tumor-associated carbonic anhydrase Ⅸ in cancer therapy [J]. Trends in Pharmacological Sciences, 2006, 27(11): 566-573.
[40]
de Simone G, Supuran CT. Carbonic anhydrase Ⅸ: Biochemical and crystallographic characterization of a novel antitumor target [J]. BBA-Proteins Proteomics, 2010, 1 804(2): 404-409.
